215 related articles for article (PubMed ID: 24690327)
1. Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution.
Janha RE; Worwui A; Linton KJ; Shaheen SO; Sisay-Joof F; Walton RT
BMC Evol Biol; 2014 Apr; 14():71. PubMed ID: 24690327
[TBL] [Abstract][Full Text] [Related]
2. Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates.
Pimenoff VN; Laval G; Comas D; Palo JU; Gut I; Cann H; Excoffier L; Sajantila A
Pharmacogenet Genomics; 2012 Dec; 22(12):846-57. PubMed ID: 23089684
[TBL] [Abstract][Full Text] [Related]
3. [Cytochrome P450 2C19 gene polymorphism in four Chinese nationality populations].
Zhang S; Dong Z; Tang L; Zhou Q; Wu Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):52-4. PubMed ID: 11836688
[TBL] [Abstract][Full Text] [Related]
4. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.
Martis S; Peter I; Hulot JS; Kornreich R; Desnick RJ; Scott SA
Pharmacogenomics J; 2013 Aug; 13(4):369-77. PubMed ID: 22491019
[TBL] [Abstract][Full Text] [Related]
5. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.
Suarez-Kurtz G; Genro JP; de Moraes MO; Ojopi EB; Pena SD; Perini JA; Ribeiro-dos-Santos A; Romano-Silva MA; Santana I; Struchiner CJ
Pharmacogenomics J; 2012 Jun; 12(3):267-76. PubMed ID: 21173785
[TBL] [Abstract][Full Text] [Related]
6. Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2.
Si D; Wang J; Zhang Y; Zhong D; Zhou H
Biopharm Drug Dispos; 2012 Sep; 33(6):342-5. PubMed ID: 22886551
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese.
Zhou Q; Yu XM; Lin HB; Wang L; Yun QZ; Hu SN; Wang DM
Pharmacogenomics J; 2009 Dec; 9(6):380-94. PubMed ID: 19636337
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China.
Chen L; Qin S; Xie J; Tang J; Yang L; Shen W; Zhao X; Du J; He G; Feng G; He L; Xing Q
Pharmacogenomics; 2008 Jun; 9(6):691-702. PubMed ID: 18518848
[TBL] [Abstract][Full Text] [Related]
9. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.
Yin SJ; Ni YB; Wang SM; Wang X; Lou YQ; Zhang GL
J Clin Pharm Ther; 2012 Jun; 37(3):364-9. PubMed ID: 21913948
[TBL] [Abstract][Full Text] [Related]
10. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Bertilsson L
Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity.
Dandara C; Lombard Z; Du Plooy I; McLellan T; Norris SA; Ramsay M
Pharmacogenomics; 2011 Dec; 12(12):1663-70. PubMed ID: 22118051
[TBL] [Abstract][Full Text] [Related]
12. Worldwide distribution of the MYH9 kidney disease susceptibility alleles and haplotypes: evidence of historical selection in Africa.
Oleksyk TK; Nelson GW; An P; Kopp JB; Winkler CA
PLoS One; 2010 Jul; 5(7):e11474. PubMed ID: 20634883
[TBL] [Abstract][Full Text] [Related]
13. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
Goldstein JA; Ishizaki T; Chiba K; de Morais SM; Bell D; Krahn PM; Evans DA
Pharmacogenetics; 1997 Feb; 7(1):59-64. PubMed ID: 9110363
[TBL] [Abstract][Full Text] [Related]
14. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
[TBL] [Abstract][Full Text] [Related]
15. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.
Hamdy SI; Hiratsuka M; Narahara K; El-Enany M; Moursi N; Ahmed MS; Mizugaki M
Br J Clin Pharmacol; 2002 Jun; 53(6):596-603. PubMed ID: 12047484
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
[TBL] [Abstract][Full Text] [Related]
17. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
[TBL] [Abstract][Full Text] [Related]
18. Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype.
Herrlin K; Massele AY; Rimoy G; Alm C; Rais M; Ericsson O; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 2000 Aug; 68(2):189-98. PubMed ID: 10976550
[TBL] [Abstract][Full Text] [Related]
19. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia.
Griese EU; Ilett KF; Kitteringham NR; Eichelbaum M; Powell H; Spargo RM; LeSouef PN; Musk AW; Minchin RF
Pharmacogenetics; 2001 Feb; 11(1):69-76. PubMed ID: 11207032
[TBL] [Abstract][Full Text] [Related]
20. Distribution of CYP2C19*17 allele and genotypes in an Indian population.
Anichavezhi D; Chakradhara Rao US; Shewade DG; Krishnamoorthy R; Adithan C
J Clin Pharm Ther; 2012 Jun; 37(3):313-8. PubMed ID: 21916910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
